Extended-release IPX-203 Reduces ‘Off’ Time in Advanced Parkinson’s
Top-line data from a Phase 3 clinical trial testing IPX-203 showed Amneal Pharmaceuticals’ carbidopa-levodopa (CD/LD) extended-release capsules work better…
Articles by Marta Figueiredo, PhD
Study Examines Proteins’ Roles in Mitochondrial Recycling
PINK1 and Parkin — two proteins whose deficiency has been linked to early-onset Parkinson’s — are involved in the degradation…
Dopamine Transporter Levels May Predict Parkinson’s Earlier
Lower levels of dopamine transporter protein in the striatum — a brain region affected significantly in Parkinson’s — may…
Excess Alpha-synuclein Directly Linked to Mitochondrial Problems
Higher-than-normal levels of alpha-synuclein — the protein that accumulates in toxic clumps in Parkinson’s disease — affect the shape,…
Worse GI Symptoms Predict Anxiety, Depression, and Vice-versa
Worse gastrointestinal symptoms predict more severe anxiety and depression, and vice-versa, within the same year and in the following year…
Discovery May Explain Conflicting DBS Results
The mesencephalic locomotor region, a brain region previously thought to control only walking and other forms of locomotion in vertebrates,…
Worse Early Non-motor Symptoms Predict Faster Function Decline
The number and severity of non-motor symptoms increase during the early stages of Parkinson’s disease, and are significantly associated…
Scientists Identify PIAS2 Protein as Driver of Parkinson’s Dementia
PIAS2, a protein that suppresses the immune interferon (IFN)-beta signaling, is found at higher-than-normal levels in neurons of sporadic…
Preclinical Study Sheds Light on How Melatonin May Protect Neurons
Treatment with melatonin — a hormone best known for its role in sleep regulation — lessened neurodegeneration and motor symptoms…
SLS-004 Lowered Alpha-synuclein Levels in Mice
SLS-004, Seelos Therapeutics’ experimental epigenetic editing therapy for Parkinson’s disease, effectively reduced the production of alpha-synuclein — the protein…